Mohammed I Aladul1, Raymond W Fitzpatrick2, Stephen R Chapman3. 1. School of Pharmacy, Keele University, Hornbeam Building, Newcastle-under-Lyme, Staffordshire ST5 5BG, United Kingdom; School of Pharmacy, University of Mosul, Mosul, Nineveh, Iraq. 2. School of Pharmacy, Keele University, Hornbeam Building, Newcastle-under-Lyme, Staffordshire ST5 5BG, United Kingdom. 3. School of Pharmacy, Keele University, Hornbeam Building, Newcastle-under-Lyme, Staffordshire ST5 5BG, United Kingdom. Electronic address: s.r.chapman@keele.ac.uk.
Abstract
BACKGROUND: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. OBJECTIVES: This study aimed to estimate the budget impact of the introduction of new biosimilars Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® in rheumatology and gastroenterology specialities in the UK. METHODS: A published budget impact model was adapted to estimate the expected cost savings following the entry of new biosimilars Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® in the UK over three-year time horizon. This model was based on retrospective market shares of biologics used in rheumatology and gastroenterology which were derived from DEFINE Software and healthcare professional perspectives. RESULTS: The model predicted that infliximab and etanercept biosimilars would replace their corresponding reference agents by 2020. Adalimumab biosimilars were predicted to achieve 19% of the rheumatology and gastroenterology market by 2020. Without the introduction of further biosimilars, the model predicted a reduction in expenditure of £44 million on biologics over the next three years. With the entry of Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® the model estimates cumulative savings of £285 million by 2020. CONCLUSIONS: The introduction of new infliximab, etanercept and adalimumab biosimilars will be associated with considerable cost savings and have a substantial favourable impact on the UK NHS budget. The number of biosimilars and time of entry of is critical to create competition which will result in maximum cost savings.
BACKGROUND: The approval of new biosimilars of infliximab, etanercept and adalimumab by the European Medicines Agency is expected to produce further cost savings to the healthcare system budget. OBJECTIVES: This study aimed to estimate the budget impact of the introduction of new biosimilars Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® in rheumatology and gastroenterology specialities in the UK. METHODS: A published budget impact model was adapted to estimate the expected cost savings following the entry of new biosimilars Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® in the UK over three-year time horizon. This model was based on retrospective market shares of biologics used in rheumatology and gastroenterology which were derived from DEFINE Software and healthcare professional perspectives. RESULTS: The model predicted that infliximab and etanercept biosimilars would replace their corresponding reference agents by 2020. Adalimumab biosimilars were predicted to achieve 19% of the rheumatology and gastroenterology market by 2020. Without the introduction of further biosimilars, the model predicted a reduction in expenditure of £44 million on biologics over the next three years. With the entry of Flixabi®, Erelzi®, Solymbic®, Amgevita® and Imraldi® the model estimates cumulative savings of £285 million by 2020. CONCLUSIONS: The introduction of new infliximab, etanercept and adalimumab biosimilars will be associated with considerable cost savings and have a substantial favourable impact on the UK NHS budget. The number of biosimilars and time of entry of is critical to create competition which will result in maximum cost savings.
Authors: Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Arianna Sgheri; Giuseppe Lopalco; Jurgen Sota; Silvana Guerriero; Florenzo Iannone; Bruno Frediani; Lorenzo Vannozzi; Maria Teresa Bianco; Valtere Giovannini; Gian Marco Tosi; Luca Cantarini Journal: Front Pharmacol Date: 2019-12-09 Impact factor: 5.810